Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.60 |
| ▸ | MTOR | P42345 | 11/20 | 0.60 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.60 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | USP7 | Q93009 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754345 | 0.86 | PIK3CA (0.45) | PIK3CAMTORPIK3CBCDK4CDK2 | |
| SCHEMBL751843 | 0.83 | PIK3CA (0.43) | PIK3CAMTORPIK3CBALDH1A1SMN1; SMN2 | |
| SCHEMBL755349 | 0.79 | PIK3CA (0.42) | PIK3CAMTORPIK3CB | |
| SCHEMBL757760 | 0.78 | PIK3CA (0.43) | PIK3CAMTORPIK3CBGAA | |
| SCHEMBL753913 | 0.77 | PIK3CA (0.60) | PIK3CAMTORPIK3CBCDK4CDK2 | |
| SCHEMBL754934 | 0.76 | PIK3CA (0.66) | PIK3CAMTORPIK3CBALDH1A1SMN1; SMN2 | |
| SCHEMBL750996 | 0.73 | PIK3CA (0.46) | PIK3CAMTORCDK4CDK2KDM4E | |
| SCHEMBL752349 | 0.73 | PIK3CA (0.65) | PIK3CAMTORPIK3CB | |
| SCHEMBL755434 | 0.73 | PIK3CA (0.64) | PIK3CAMTORPIK3CB | |
| SCHEMBL757605 | 0.72 | PIK3CA (0.68) | PIK3CAMTORPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | PIK3CA 1/4885MTOR 21/4885PIK3CB 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.